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The collateral and extended effects of preven-tive chemotherapy, many of which were un-anticipated, have reduced disease burdens 
and saved lives on a scale that appears to have ex-
ceeded the intended impact on 
seven neglected tropical diseases 
(NTDs) — the three major soil-
transmitted helminth infections 
(ascariasis, trichuriasis, and hook-
worm infection), schistosomiasis, 
lymphatic filariasis, onchocercia-
sis, and trachoma.
The concept of integrated pro-
grams of mass drug administra-
tion (also referred to as preventive 
chemotherapy) was first proposed 
in the early 2000s, and such in-
terventions now reach more than 
1 billion people per year in low- 
and middle-income countries of 
Africa, Asia, and Latin America.1 
Implementation of the World 
Health Organization (WHO) pre-
ventive chemotherapy strategy has 
resulted in substantial reductions 
in the disease burden and disabil-
ity-adjusted life years (DALYs, or 
lost years of healthy life) — as 
much as a 46% decrease in DALYs 
— attributable to the seven NTDs, 
allowing some countries to achieve 
their elimination targets for tra-
choma, lymphatic filariasis, and 
onchocerciasis. Moreover, it has 
led to cost savings for the world’s 
poorest people, by reducing cata-
strophic health expenditures.1
Scientists and public health ex-
perts realized at the outset of 
this program that the primary 
drugs used for preventive chemo-
therapy, including albendazole 
or mebendazole, ivermectin, pra-
ziquantel, and azithromycin, might 
affect conditions beyond their 
originally intended targets. Now, 
nearly 15 years after mass drug 
administration for NTDs was first 
proposed, the existence of such 
collateral benefits can be verified 
(see table).
In an Australian aboriginal 
community, a single dose of iver-
mectin (200 μg per kilogram of 
body weight) delivered in two 
community mass drug adminis-
trations 12 months apart not only 
prevented ascariasis, trichuriasis, 
and hookworm infections, but also 
significantly reduced the preva-
lence of strongyloidiasis. A simi-
lar effect on strongyloidiasis was 
achieved in Cambodia with a sin-
gle mass ivermectin administra-
tion. Ivermectin also reduces the 
prevalence of loiasis (human Loa 
loa infection) in places where both 
onchocerciasis and loiasis are en-
demic. A recently published clin-
ical trial suggests that ivermectin 
could help reduce the prevalence 
of mansonelliasis in the Amazon, 
although it’s less clear whether 
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this effect could be replicated in 
Africa. In addition, mass admin-
istration of albendazole appears 
to have reduced the prevalence of 
oesophagostomiasis (Oesophagosto-
mum bifurcum infection) in humans, 
even to the point of elimination 
in northern Ghana and Togo. 
Mass administration of single-
dose praziquantel for schistoso-
miasis also appears to be effective 
for the treatment of opisthorchi-
asis (in Southeast Asia) and hu-
man tapeworm infections.
Furthermore, preventive chemo-
therapy is showing substantial 
collateral benefits for two neglect-
ed skin diseases — scabies and 
yaws.2,3 Although the Global Bur-
den of Disease Study does not 
provide estimates for yaws, it has 
revealed that scabies (and its as-
sociated secondary bacterial infec-
tions, especially impetigo) has one 
of the largest public health effects 
among the NTDs. Beginning in 
2012, large-scale studies, includ-
ing randomized clinical trials, 
conducted in the South Pacific 
and Africa showed the benefits 
of mass administration of iver-
mectin for scabies.2 The Interna-
tional Alliance for the Control of 
Scabies has been leading global 
efforts to raise awareness about 
scabies and impetigo, promoting 
the addition of scabies to the 
WHO list of NTDs and high-
lighting mass drug administra-
tion as an appropriate intervention 
strategy.2 Similarly, mass admin-
istration of azithromycin designed 
for trachoma elimination has 
shown enormous promise for the 
treatment and elimination of 
yaws.3 A major study from Papua 
New Guinea in 2015 found that 
mass azithromycin administration 
substantially reduced the preva-
lence of yaws,3 as did a single 
round of such treatment in Ghana.
More recent studies have 
shown that plasma containing 
ivermectin has the capacity to re-
duce transmission of Plasmodium 
vivax malaria, thanks to the drug’s 
effects on the viability of both 
anopheles mosquito vectors and 
the malaria parasites themselves. 
In Kenya, among adults treated 
with both high-dose ivermectin 
and dihydroartemisinin–pipera-
quine, blood containing ivermec-
tin was shown to reduce survival 
of Anopheles gambiae mosquitoes 
that fed on it, which suggests that 
this approach could also help in 
controlling P. falciparum malaria.4 
These results, though exciting, are 
still preliminary, and the ques-
tion of whether mass administra-
tion of ivermectin in the appropri-
ate doses for control of lymphatic 
filariasis and onchocerciasis might 
also reduce malaria transmission 
has yet to be investigated.
In 2009, in a trachoma-endemic 
area of Ethiopia, mass azithro-
mycin administration was found 
to be associated with dramatic 
reductions in overall child mor-
tality. The findings were consid-
ered astonishing, given that tra-
choma is not a fatal childhood 
infection, and it was hard to 
understand how a single dose of 
azithromycin would affect the 
outcome of serious bacterial co-
infections such as pneumonia or 
diarrheal disease. But in a large, 
randomized follow-up study in 
Malawi, Niger, and Tanzania, the 
MORDOR (Macrolides Oraux pour 
Réduire les Décès avec un Oeil sur 
la Résistance) group confirmed 
that overall child mortality was 
lower among preschool children 
who received azithromycin.5 The 
public health effect occurs pri-
marily in the first 3 months af-
ter the distribution of the drug, 
which suggests that azithromycin 
could have substantial benefits if 
administered to populations more 
frequently than once, or even 
twice, per year. A follow-up 
MORDOR II study is planned for 
Burkina Faso to test these, and 
other, ideas.
Since the original drug pack-
aging for the preventive chemo-
therapy strategy was proposed, 
some exciting possibilities have 
been identified for drug substitu-
tions or additions. Among these 
possibilities are new anthelmintic 
agents, such as tribendimidine (for 
foodborne trematodiases and soil-
transmitted helminth infections); 
the addition of either tribendimi-
dine or oxantel pamoate to alben-
dazole, to increase the efficacy 
of treatment for trichuriasis and 
hookworm; and moxidectin (re-
Drug Original Targets Extended Targets
Albendazole or  
mebendazole
Ascariasis 
Trichuriasis 
Hookworm infection
Oesophagostomiasis 
Strongyloidiasis
Ivermectin Lymphatic filariasis 
Onchocerciasis
Scabies 
Strongyloidiasis 
Loiasis 
Mansonelliasis 
Malaria transmission
Praziquantel Schistosomiasis Foodborne trematodiases 
Taeniasis
Azithromycin Trachoma Yaws 
Child mortality
Extended Targets of Medications Used for Preventive Chemotherapy against NTDs.
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cently approved by the Food and 
Drug Administration) in place of 
ivermectin in some settings. A fur-
ther proposed addition is nitazox-
anide to target the intestinal 
protozoa giardia and cryptosporid-
ium. Finally, recent studies have 
indicated that chemoprophylaxis 
with single-dose rifampin in 
household contacts of people 
with leprosy may reduce leprosy 
transmission and prevalence in 
some settings. These medications 
require additional clinical testing 
and regulatory approvals or oper-
ational research before they can 
be fully incorporated into the pre-
ventive chemotherapy package. 
New vaccines against NTDs are 
also under development.
One concern regarding mass 
drug administration, especially 
with azithromycin, is the poten-
tial emergence of drug resistance 
both to the intended target path-
ogens for trachoma, yaws, and 
leprosy and to colonizing respira-
tory and gastrointestinal patho-
genic bacteria. So far, mass azith-
romycin administration has been 
shown not to elicit drug resis-
tance in Chlamydia trachomatis, but 
it may elicit azithromycin-resistant 
yaws. Moving forward, it will be 
essential to monitor preventive 
chemotherapy programs for the 
possible emergence of drug- 
resistant respiratory and gastro-
intestinal bacterial pathogens, 
and anthelmintic drug resistance 
may also emerge. A further con-
sideration is the integration of 
preventive chemotherapy for NTDs 
with approaches to preventing 
malaria and HIV/AIDS.1 For exam-
ple, the findings regarding iver-
mectin’s effect on malaria may 
inspire greater interaction between 
NTD- and malaria-prevention pro-
grams, and there is also renewed 
interest in treating female genital 
schistosomiasis in adolescence as a 
strategy for preventing HIV/AIDS.
Expanding the public health 
impact of preventive chemother-
apy would significantly increase 
years of healthy life for people in 
affected regions and would be 
highly cost-effective. The mass 
drug administration platform is 
a successful manifestation of uni-
versal health coverage, and the 
broader range of NTD-control 
strategies contributes to progress 
toward the United Nations’ Sus-
tainable Development Goals. Such 
assessments are key advocacy mes-
sages that encourage further in-
vestments in NTD programs, 
which deploy a proven strategy 
that reaches more than a billion 
of the world’s most vulnerable 
people each year.
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